Trial Profile

A Cancer Research UK Phase I/II Trial of ALETA-001 in Participants Who Have Received an Anti-CD19 CAR T-Cell Therapy for the Treatment of B-cell Malignancies

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALETA-001 (Primary)
Indications B-cell leukaemia; B-cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

31 May 2025 Mantle cell lymphoma is added to indications.
31 May 2025 Planned number of patients changed from 72 to 84.
31 May 2025 Planned End Date changed from 1 Dec 2027 to 1 Feb 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com